ClinicalTrials.gg
RecruitingNCT06514976Updated Nov 19, 2026

Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy

An observational study in Stroke, Acute and Stroke, Ischemic, sponsored by POLYSAN Scientific & Technological Pharmaceutical Company. Recruiting at 17 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by POLYSAN Scientific & Technological Pharmaceutical Company · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Nov 19, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
562
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 17 studies in Ischemic Stroke with a site in Russia — 13 open to participants now, 13 under way, 2 of them phase 3. Ischemic Stroke · Russia.

Started
2024
with 3 others
Observational
8 of 17
5 open now
Primary completion
2027-06
later than 8 of 12 live
Registered
7th of 17
by date
Lead sponsor
2 of 17
POLYSAN Scientific & Technological Pharmaceutical Company

Among the 17 studies in Ischemic Stroke with a site in Russia, this one is one of 4 that started in 2024, is one of 8 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 7th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

13 of the 17 studies in Ischemic Stroke with a site in Russia are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Ischemic Stroke with a site in Russia, or all of them as a file.
02

Study summary

Stroke remains one of the main socially significant problems in the healthcare in the third millennium. The lethality in persons with history of stroke by the end of the 1st year of disease is high. A trend to increased frequency of stroke in the young age is observed during the last decade; third of patients is working-age individuals, out of whom only 15-20% returns to labor, and others remain disabled persons requiring constant medical and social support

03

Conditions studied

  • Stroke, Acute
  • Stroke, Ischemic

Browse trials for

Keywords

  • stroke
  • сytoflavin
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 562 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

POLYSAN Scientific & Technological Pharmaceutical Company is the lead sponsor of 24 studies on the registry; 4 are open to participants now.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients aged above 18 years with diagnosis of ACVA of ischemic type who did not receive and are not scheduled for reperfusion therapy (thrombolysis, thrombus extraction).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form
  2. Age from 18 years and older
  3. Diagnosis: Acute cerebrovascular accident of ischemic type (ischemic stroke) developed within 36 hours before enrollment in the study
  4. Motor neurologic deficit measurable using the NIHSS Scale (score for item 5 and/or 6 at the time of starting the therapy ≥ 1))
  5. Conservative stroke treatment tactics (without reperfusion therapy thrombolysis/thrombus extraction)
  6. According to the routine clinical practice, the patient is scheduled to receive the treatment as per one of the following regimens:

    • Cytoflavin® 20-40 ml/day as a course of not less than 10 days or
    • another neuroprotector - course of not less than 10 days (or without neuroprotector)

Exclusion criteria

Exclusion Criteria:

  1. NIHSS 1a (coma) score 3 at the time of enrollment
  2. Initial severe disablement (corresponding to mRS > 2) requiring external assistance in everyday life before development of stroke
  3. History of Parkinson's disease, dementia, multiple sclerosis, and other significant diseases accompanied by neurologic deficit
  4. Severe comorbidity with expected lifespan of not more than 6 months
  5. Pregnancy and breastfeeding
  6. Any other concomitant medical or serious psychic conditions, which make the patient ineligible for participation in the study, restrict lawfulness of obtaining the , or can influence the patient's ability to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
562 participants (estimated)
Patient registry
No

Groups and cohorts

  • The test group

    Basic therapy + Cytoflavin

    Drug: Cytoflavin

  • The control group

    Basic therapy (with or without other neuroprotector)

Interventions

  • Cytoflavin solution for infusions. 20-40 ml/day (10 ml with the interval of 8-12 hours for 10 days; the single dose is increased up to 20 ml in case of the severe form of the disease) by intravenous drop infusion in dilution per 100-200 ml of 0.9% sodium chloride solution for 10 days; rate of administration: 3-4 ml/min

07

What researchers measure

Primary outcomes

  1. Percentage of patients with favorable functional outcome (score 0-2) according to Modified Rankin Scale (mRS) on Day of Discharge (assessment at Visit 4 or Visit 5, on Day of Discharge) and on Day 90;

    Modified Rankin Scale (mRS)

    Time frame: Base, day 14, day 21, day 90

Secondary outcomes

  1. Total score according to Modified Rankin Scale (mRS) on Day of Discharge and Day 90 in the test and control group;

    Modified Rankin Scale (mRS)

    Time frame: Day 14, day 21, day 90

  2. Total score according to Rivermead Scale on Day 7, Day 14, Day 21, and Day 90 in the test and control group

    Rivermead Scale

    Time frame: Day 7, day 14, day 21, day 90

  3. Change of the total score according to National Institute of Health Stroke Scale (NIHSS) on Day 3, Day 7, Day 14, and Day 21 as compared to the baseline level (Day 1);

    National Institute of Health Stroke Scale (NIHSS)

    Time frame: Day 7, day 14, day 21, day 90

  4. Change of the total score according to Stroke-Specific Quality of Life Scale (SS-QOL) on Day 90 as compared to Day of Discharge;

    Stroke-Specific Quality of Life Scale (SS-QOL)

    Time frame: Day 14, day 21, day 90

  5. Percentage of patients with repeated ACVA or TIA during the study;

    Repeated ACVA or TIA

    Time frame: Day 90

  6. Percentage of patients with lethal outcome in the period of hospitalization and follow-up

    Lethal outcome

    Time frame: Day 90

08

Study locations

17 of 17 sites recruiting
  • "Ivanovo Regional Clinical Hospital"
    Ivanovo, Russia
    Recruiting
  • Kazan State Medical University
    Kazan', Russia
    Recruiting
  • State Autonomous Institution of Health Interregional clinical diagnostic center
    Kazan', Russia
    Recruiting
  • Moscow City Clinical Hospital No.64 (CCH named after V.V. Vinogradov)
    Moscow, Russia
    Recruiting
  • N.I. Pirogov City Clinical Hospital No. 1
    Moscow, Russia
    Recruiting
  • Vorohobov's City Clinical Hospital №67
    Moscow, Russia
    Recruiting
  • City Clinical Hospital No. 1 Novosibirsk
    Novosibirsk, Russia
    Recruiting
  • Alexandrovskaya hospital
    Saint Petersburg, Russia
    Recruiting
  • Almazov National Medical Research Centr
    Saint Petersburg, Russia
    Recruiting
  • City Mariinsky Hospital
    Saint Petersburg, Russia
    Recruiting
  • Nikolaevskaya Hospital
    Saint Petersburg, Russia
    Recruiting
  • Saint-Petersburg I. I. Dzhanelidze research institute of emergency medicine
    Saint Petersburg, Russia
    Recruiting
  • St. Petersburg State Budgetary Institution of Public Health "City Hospital No. 40 of Kurortny District"
    Saint Petersburg, Russia
    Recruiting
  • The City Hospital of the Holy Martyr Elizabeth
    Saint Petersburg, Russia
    Recruiting
  • Smolensk Regional Clinical Hospital
    Smolensk, Russia
    Recruiting
  • Municipal Clinical Hospital #13, the City of Ufa, State Budgetary Healthcare Institution of the Republic of Bashkortostan
    Ufa, Russia
    Recruiting
  • Budgetary healthcare institution of the Voronezh region "Voronezh Regional Clinical Hospital No. 1"
    Voronezh, Russia
    Recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jun 2027, 39 months after the start.

Of 42 industry-sponsored observational studies under Ischemic Stroke, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 39 months is above that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Sep 2025 → Jun 2027 and completion Nov 2025 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Jul 23, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Jun 1, 2027was Sep 2025
CompletionEst.
Aug 1, 2027was Nov 2025
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Russia)
  • Kazan State Medical University · Kazan', Russia
  • State Autonomous Institution of Health Interregional clinical diagnostic center · Kazan', Russia
Show 2 removed
  • Kazan State Medical University · Kazan, Russian Federation
  • State Autonomous Institution of Health Interregional clinical diagnostic center · Kazan, Russian Federation
Nov 19, 2026
Primary completion
Sep 30, 2025→Jun 1, 2027
Nov 19, 2026
Study completion
Nov 1, 2025→Aug 1, 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Russia)
    • Kazan State Medical University · Kazan', Russia
    • State Autonomous Institution of Health Interregional clinical diagnostic center · Kazan', Russia
    Show 2 removed
    • Kazan State Medical University · Kazan, Russian Federation
    • State Autonomous Institution of Health Interregional clinical diagnostic center · Kazan, Russian Federation
    Primary completion Sep 30, 2025→Jun 1, 2027
    Study completion Nov 1, 2025→Aug 1, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06514976
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Mar 1, 2024
Primary completion
Jun 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Alexey Kovalenko, Doc Biol Sci
Contact
science@polysan.ru
+78127108225 ext. 212

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion